Haematologica · 2023 · 10 citations · 37 references
Life SciencesHematologyImmunologyImmunoregulationStem Cell TransplantationTransplant ImmunologyCell-mediated ImmunityGraft-versus-host DiseaseRegulatory T CellsT Cell Activation ControlT Cell BiologyTransplant ImmunotherapyAlloreactive T Cell ResponsesGraft Versus Host Disease ModulationGraft-versus-host Disease PathophysiologyGraft-versus-host Immune ModulationHematopoietic Stem Cell Transplantation ImmunotherapyNatural Regulatory T CellsPeripheral Regulatory T CellsT Cell-based Immunotherapy
Modulating an immune response in opposite directions represents the holy grail in allogeneic hematopoietic stem cell transplantation (allo-HSCT) to avoid insufficient reactivity of donor T cells and hematologic malignancy relapse while controlling the potential development of graft-versus-host disease (GVHD), in which donor T cells attack the recipient's tissues. IL-2/anti-IL-2 complexes (IL-2Cx) represent a therapeutic option to selectively accentuate or dampen the immune response. In dedicated experimental models of allo-HSCT, including also human cells injected in immunodeficient NSG mice, we evaluated side-by-side the therapeutic effect of two IL-2Cx designed either to boost regulatory T cells (Treg) or alternatively to activate effector T cells (Teff), on GVHD occurrence and tumor relapse. We also evaluated the effect of the complexes on the phenotype and function of immune cells in vivo. Unexpectedly, both pro-Treg and pro-Teff IL-2Cx prevented GVHD development. They both induced Treg expansion and reduced CD8+ T-cell numbers, compared to untreated mice. However, only mice treated with the pro-Treg IL-2Cx, showed a dramatic reduction of exhausted CD8+ T cells, consistent with a potent anti-tumor effect. When evaluated on human cells, pro-Treg IL-2Cx also preferentially induced Treg expansion in vitro and in vivo, while allowing the development of a potent anti-tumor effect in NSG mice. Our results demonstrate the clinical relevance of using a pro-Treg, but not a pro-Teff IL2Cx to modulate alloreactivity after HSCT, while promoting a graft-versus-leukemia effect.
37
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
John Koreth, Ken‐ichi Matsuoka, Haesook T. Kim et al. · New England Journal of Medicine · 2011 · 1.1K citations · Full text
Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes
Onur Boyman, Marek Kovář, Mark P. Rubinstein et al. · Science · 2006 · 868 citations
CD4+CD25+ Immunoregulatory T Cells
José L. Cohen, Aurélie Trenado, D. Vasey et al. · The Journal of Experimental Medicine · 2002 · 681 citations · Full text